Palvella Therapeutics Strengthens QTORIN Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant genetic skin disease affecting an estimated more than 50,000 diagnosed patients in th...